Show simple item record

dc.contributor.authorAlnabulsi, A
dc.contributor.authorWang, T
dc.contributor.authorPang, W
dc.contributor.authorIonescu, M
dc.contributor.authorCraig, SG
dc.contributor.authorHumphries, MP
dc.contributor.authorMcCombe, K
dc.contributor.authorSalto Tellez, M
dc.contributor.authorAlnabulsi, A
dc.contributor.authorMurray, GI
dc.date.accessioned2022-04-13T09:02:04Z
dc.date.available2022-04-13T09:02:04Z
dc.date.issued2022-05-01
dc.identifier.citationThe journal of pathology. Clinical research, 2022, 8 (3), pp. 245 - 256
dc.identifier.issn2056-4538
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5081
dc.identifier.eissn2056-4538
dc.identifier.eissn2056-4538
dc.identifier.doi10.1002/cjp2.258
dc.identifier.doi10.1002/cjp2.258
dc.description.abstractColorectal carcinoma is one of the most common types of malignancy and a leading cause of cancer-related death. Although clinicopathological parameters provide invaluable prognostic information, the accuracy of prognosis can be improved by using molecular biomarker signatures. Using a large dataset of immunohistochemistry-based biomarkers (n = 66), this study has developed an effective methodology for identifying optimal biomarker combinations as a prognostic tool. Biomarkers were screened and assigned to related subsets before being analysed using an iterative algorithm customised for evaluating combinatorial interactions between biomarkers based on their combined statistical power. A signature consisting of six biomarkers was identified as the best combination in terms of prognostic power. The combination of biomarkers (STAT1, UCP1, p-cofilin, LIMK2, FOXP3, and ICOS) was significantly associated with overall survival when computed as a linear variable (χ2  = 53.183, p < 0.001) and as a cluster variable (χ2  = 67.625, p < 0.001). This signature was also significantly independent of age, extramural vascular invasion, tumour stage, and lymph node metastasis (Wald = 32.898, p < 0.001). Assessment of the results in an external cohort showed that the signature was significantly associated with prognosis (χ2  = 14.217, p = 0.007). This study developed and optimised an innovative discovery approach which could be adapted for the discovery of biomarkers and molecular interactions in a range of biological and clinical studies. Furthermore, this study identified a protein signature that can be utilised as an independent prognostic method and for potential therapeutic interventions.
dc.formatPrint-Electronic
dc.format.extent245 - 256
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectPrognosis
dc.subjectImmunohistochemistry
dc.subjectAlgorithms
dc.subjectBiomarkers, Tumor
dc.titleIdentification of a prognostic signature in colorectal cancer using combinatorial algorithm-driven analysis.
dc.typeJournal Article
dcterms.dateAccepted2021-12-23
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1002/cjp2.258
dc.relation.isPartOfThe journal of pathology. Clinical research
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Integrated Pathology
pubs.publication-statusAccepted
pubs.volume8
pubs.embargo.termsNot known
icr.researchteamIntegrated Pathology
dc.contributor.icrauthorSalto-Tellez, Manuel


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/